Other substances

Apixaban

A selective factor Xa inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
16
 AI-suggested references
8
 Clinical trials

General information

Apixaban on DrugBank
Apixaban on PubChem

Marketed as

APIXABAN; ELIQUIS

 

Structure image - Apixaban

COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N

Supporting references

Link Tested on Impact factor Notes Publication date
Inhibition of SARS-CoV-2 main protease 3CLpro by means of α-ketoamide and pyridone-containing pharmaceuticals using in silico molecular docking
3CLpro Small molecule In silico 		in silico 2.46

Predicted to inhibit the SARS-CoV-2 3C-like protease.

 Jul/10/2020

AI-suggested references

Link Publication date
Community Birth: The Value of Collaboration.
Oct/29/2020
Comparison of Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Bioprosthetic Heart Valves.
Apr/05/2022
Warfarin Versus Direct Oral Anticoagulants For Patients Needing Treatment For Distal Deep Vein Thrombosis.
Feb/03/2022
Treatments Associated with Lower Mortality among Critically Ill COVID-19 Patients: A Retrospective Cohort Study.
Feb/10/2021
Successful Treatment of Vaccine-Induced Immune Thrombotic Thrombocytopenia in a 26-Year-Old Female Patient
Mar/15/2022
Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory Disease.
Nov/23/2020
Antiviral anticoagulation
Dec/15/2021
Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19.
Jun/11/2020
Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial.
Oct/11/2021
Evaluation of Xa inhibitors as potential inhibitors of the SARS-CoV-2 Mpro protease
Jan/11/2022
Anticoagulation in Patients With COVID-19
Dec/11/2021
COVID-19 with essential thrombocythemia treated with apixaban for antithrombotic prophylaxis
Nov/30/2021
Inhibition of SARS-CoV-2 main protease 3CLpro by means of alpha-ketoamide and pyridone-containing pharmaceuticals using in silico molecular docking.
Jul/10/2020
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality
Nov/13/2020
Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone
May/24/2021
Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience
Jan/18/2022

Clinical trials

ID Title Status Phase Start date Completion date
NCT04746339 Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 Recruiting Phase 4 Mar/04/2021 Dec/01/2021
  • Alternative id - 004/2020
  • Interventions - Drug: Apixaban 2.5 MG|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital Maternidade São Vicente de Paulo, Barbalha, Ceará, Brazil|Hospital Israelita Albert Einstein, São Paulo, SP, Brazil|Hospital Universitário São Francisco de Assis, Bragança Paulista, São Paulo, Brazil|Hospital Santa Paula, São Paulo, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 1000
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of days alive and out of hospital or emergency department|Hospitalization due to bleeding|Hospitalizations for cardiopulmonary causes|All-cause hospitalization|All-cause death|Days free of venous thromboembolism|Major cardiovascular events (MACE)
NCT04650087 COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis Recruiting Phase 3 Feb/15/2021 Aug/01/2022
  • Alternative id - Pro00107078
  • Interventions - Drug: Apixaban 2.5 MG|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Valleywise Health Medical Center, Phoenix, Arizona, United States|Dignity Health-St Josephs, Phoenix, Arizona, United States|Central Arkansas Veterans Health Care System, Little Rock, Arkansas, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|National Institute of Clinical Research, Inc. Healthcare System 2000, Garden Grove, California, United States|Emanate Health (Reddy Medical Center), Pomona, California, United States|New Ananda Medical and Urgent Care, Inc., S. El Monte, California, United States|UCSF at Zuckerberg San Francisco General Hospital, San Francisco, California, United States|Mazur and Statner MD PC, Thousand Oaks, California, United States|Torrance Medical Center, Torrance, California, United States|Penrose Hospital, Colorado Springs, Colorado, United States|St. Francis Medical Center, Colorado Springs, Colorado, United States|Centura Health Porter Adventist Hospital, Denver, Colorado, United States|Saint Anthony Hospital, Lakewood, Colorado, United States|St. Anthony North Health Campus, Westminster, Colorado, United States|Baycare Hospital, Clearwater, Florida, United States|Florida Heart Center, Fort Pierce, Florida, United States|University of Florida, Gainesville, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Tallahassee Memorial HealthCare, Tallahassee, Florida, United States|James A. Haley Veteran's Hospital, Tampa, Florida, United States|Triple O Research Institute, P.A., West Palm Beach, Florida, United States|BayCare Hospital- Winter Haven, Winter Haven, Florida, United States|Emory University, Atlanta, Georgia, United States|Medical College of Georgia/Augusta University, Augusta, Georgia, United States|Savannah Health Services, LLC DBA Memorial Health University Medical Center, Savannah, Georgia, United States|Queens Medical Center, Honolulu, Hawaii, United States|Hawaii Pacific Health, Honolulu, Hawaii, United States|Snake River Research, PLLC, Idaho Falls, Idaho, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Cook County Health, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|The University of Chicago Medicine, Chicago, Illinois, United States|OSF Little Company of Mary, Evergreen Park, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Indiana University Health Bloomington Hospital, Bloomington, Indiana, United States|Lutheran Medical Group, Fort Wayne, Indiana, United States|Indiana University Health Methodist Hospital, Indianapolis, Indiana, United States|Franciscan Health Michigan City, Michigan City, Indiana, United States|Reid Physician Associates, Richmond, Indiana, United States|Baptist Health Lexington, Lexington, Kentucky, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Ochsner Clinic Foundation-Baton Rouge, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Willis-Knighton Physician Network/Tri-State Medical Clinic, Shreveport, Louisiana, United States|Maine Medical Center/Maine Medical Partners Adult Hospital Medicine, Portland, Maine, United States|Pen Bay Medical Center, Rockport, Maine, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Lifebridge (Sinai Hospital of Baltimore), Baltimore, Maryland, United States|Adventist HealthCare Shady Grove Medical Center, Rockville, Maryland, United States|Boston University, Boston, Massachusetts, United States|Lahey Hospital and Medical Center, Burlington, Massachusetts, United States|Baystate Medical center, Springfield, Massachusetts, United States|Bay Regional Medical Center d/b/a/ McLaren Bay Region, Bay City, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Western Michigan University, Kalamazoo, Michigan, United States|MidMichigan Medical Center, Midland, Michigan, United States|McLaren Macomb, Mount Clemens, Michigan, United States|Minneapolis VA Health Care System, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Truman Medical Center, Kansas City, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Mercury Street Medical Group, Butte, Montana, United States|CHI St Elizabeth Hospital, Lincoln, Nebraska, United States|Renown Health, Reno, Nevada, United States|Dartmouth Hichcock Medical Center, Lebanon, New Hampshire, United States|AtlantiCare Regional Medical Center, Atlantic City, New Jersey, United States|Hope Tower at Jersey Shore University Medical Center, Neptune, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|Capital Health System, Inc., Trenton, New Jersey, United States|Christus St. Vincent Regional Medical Center, Santa Fe, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|NYU Langone Hospital-Brooklyn, Brooklyn, New York, United States|Coney Island Hospital, Brooklyn, New York, United States|Buffalo General Medical Center, Buffalo, New York, United States|Mercy Hospital Buffalo, Buffalo, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|New York University Langone Health, New York, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Westchester Medical Center, Valhalla, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke Medical Center, Durham, North Carolina, United States|East Carolina University/Vidant Health, Greenville, North Carolina, United States|Wake Med Hospital, Raleigh, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|Summa Health, Akron, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Ascension St. John Bartlesville, Tulsa, Oklahoma, United States|Ascension St. John Tulsa, Tulsa, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|St. Luke's University Health Network, Easton, Pennsylvania, United States|Conemaugh Memorial Medical Center, Johnstown, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Tower Health Medical Group, West Reading, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States|Monument Health Clinical Research, Rapid City, South Dakota, United States|Erlanger Health System, Chattanooga, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Christus St. Elizabeth Hospital, Beaumont, Texas, United States|Baylor Scott and White Medical Center- College Station, College Station, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Texas Health Harris Methodist, Fort Worth, Texas, United States|University of Texas- Houston, LBJ Hospital, Houston, Texas, United States|UT Houston MHH-SW, Houston, Texas, United States|UTHouston, Houston, Texas, United States|Texas Health Frisco, Plano, Texas, United States|Baylor Scott and White-Round Rock, Round Rock, Texas, United States|Baylor Scott and White-Temple, Temple, Texas, United States|The Woodlands Center For Respiratory & Sleep Research, The Woodlands, Texas, United States|CHRISTUS Trinity Clinic Pulmonary Medicine, Tyler, Texas, United States|The University of Texas Health Science Center at Tyler, Tyler, Texas, United States|UT Health East Texas (Tyler), Tyler, Texas, United States|UT Rio Grande Valley, Weslaco, Texas, United States|MultiCare Institute for Research & Innovation, Puyallup, Washington, United States|UW Medicine Valley Medical Center, Renton, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|CAMC Clinical Trials Center, Charleston, West Virginia, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|Blood Center of Wisconsin, Milwaukee, Wisconsin, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 5320
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Composite outcome of symptomatic deep vein thrombosis, pulmonary embolism, other venous thromboembolism, ischemic stroke, myocardial infarction, other arterial thromboembolism, and all-cause mortality as measured by hospital records.|The composite outcome of symptomatic deep vein thrombosis, pulmonary embolism, other venous thromboembolism, ischemic stroke, myocardial infarction, other arterial thromboembolism, and all-cause mortality as measured by hospital records.|New, symptomatic VTE (inclusive of DVT, PE, or other venous thrombosis) for up to 30 days after randomization as measured by hospital records.|New, symptomatic ATE (inclusive of ischemic stroke, MI, or peripheral arterial thromboembolism) for up to 30 days after randomization as measured by hospital records.
NCT04498273 COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Terminated Phase 3 Sep/07/2020 Aug/05/2021
  • Alternative id - ACTIV4-Outpatient
  • Interventions - Drug: Apixaban 2.5 MG|Drug: Apixaban 5MG|Drug: Aspirin|Drug: Placebo
  • Study type - Interventional
  • Study results - Has Results
  • Locations - University of Southern California, Los Angeles, California, United States|Stanford University School of Medicine, Palo Alto, California, United States|Zuckerberg San Francisco General, San Francisco, California, United States|Olive View-UCLA Medical Center, Sylmar, California, United States|Pine Ridge Family Medicine, Colorado Springs, Colorado, United States|Life Tree Health, Inc., Washington, District of Columbia, United States|Midland Florida Clinical Research Center, LLC, DeLand, Florida, United States|University of Florida at Gainesville, Gainesville, Florida, United States|Vital Pharma Research, Hialeah, Florida, United States|Advanced Research for Health Improvement, LLC, Immokalee, Florida, United States|University of Floridia at Jacksonville, Jacksonville, Florida, United States|Lakeland Regional, Lakeland, Florida, United States|Total Research Group LLC, Miami, Florida, United States|Jackson Memorial, Miami, Florida, United States|Well Pharma Medical Research, Miami, Florida, United States|Innovation Clinical Trials, Palmetto Bay, Florida, United States|Bond Community Health Center, Tallahassee, Florida, United States|Tallahassee Memorial, Tallahassee, Florida, United States|USF Tampa General Hospital, Tampa, Florida, United States|Alliance Clinical Research, Tampa, Florida, United States|Hawaii Pacific Health, Honolulu, Hawaii, United States|Fox Valley Clinical Research Center, LLC, Aurora, Illinois, United States|UIC - Mile Square, Chicago, Illinois, United States|Jesse Brown VA, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Olivo Wellness Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Ascension Via Christi, Wichita, Kansas, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Jadestone Clinical Research, LLC, Gaithersburg, Maryland, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|GFC of Southeastern Michigan, Detroit, Michigan, United States|SRI International, Plymouth, Michigan, United States|Metro Health-University of Michigan Health, Wyoming, Michigan, United States|Raritan Bay Primary Care and Cardiology Associates, Matawan, New Jersey, United States|G&S Medical Associates, LLC, Paterson, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Strong Memorial, Rochester, New York, United States|Spinal Pain and Rehab Medicine, Yonkers, New York, United States|Duke, Durham, North Carolina, United States|Peters Medical Research, High Point, North Carolina, United States|The Heart and Medical Center, Durant, Oklahoma, United States|Ascension St. John Clinical Research Institute, Tulsa, Oklahoma, United States|UPMC Passavant Cranberry, Cranberry, Pennsylvania, United States|UPMC McKeesport, McKeesport, Pennsylvania, United States|UPMC East, Monroeville, Pennsylvania, United States|UPMC Magee, Pittsburgh, Pennsylvania, United States|UPMC Presby, Pittsburgh, Pennsylvania, United States|UPMC Mercy, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|UPMC Shadyside, Pittsburgh, Pennsylvania, United States|UPMC Passavant McCandless, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Inc, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Pharma Tex Research, Amarillo, Texas, United States|Ascension Seton Medical Center, Austin, Texas, United States|Baptist Beaumont, Beaumont, Texas, United States|McGoven Medical School - UT- Houston, Houston, Texas, United States|Diversifield Medical Practices, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States|Mesquite Regional Internal Medicine, Mesquite, Texas, United States|University of Texas at Tyler, Tyler, Texas, United States|University of Texas at Rio Grande Valley, Weslaco, Texas, United States|Intermountain Healthcare, Murray, Utah, United States|Community Care of Clay, Clay, West Virginia, United States|University Healthcare Physicians, Harpers Ferry, West Virginia, United States|Community Care of Weston, Weston, West Virginia, United States|Gundersen Health System, La Crosse, Wisconsin, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 657
  • Age - 40 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Hospitalization for Cardiovascular/Pulmonary Events
NCT04801940 HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID) Recruiting Phase 3 May/19/2021 Jan/31/2024
  • Alternative id - A095848
  • Interventions - Drug: Apixaban|Drug: Atorvastatin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Addenbrookes Hospital, Cambridge, United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 2631
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Hospital free survival.|All-cause mortality|Hospital readmission after discharge from index hospital admission|Suspected Serious Adverse Reactions|FACIT-Fatigue|Modified MRC Dyspnoea Scale|COVID-19 core outcome measure for recovery|Patient Health Questionnaire-2 (PHQ-2)|Generalized Anxiety Disorder-2 (GAD-2)|PTSD Checklist (PCL-2)|Quality of life using the EQ5D-5L|Intervention tolerability using the FACT-GP5|Additional disease specific systemic symptoms
NCT04512079 FREEDOM COVID-19 Anticoagulation Strategy Recruiting Phase 4 Sep/08/2020 Jul/01/2022
  • Alternative id - GCO 20-2115
  • Interventions - Drug: Enoxaparin|Drug: Apixaban
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Icahn School of Medicine at Mount Sinai, New York, New York, United States|Instituto do Coração - INCOR, São Paulo, Brazil|Instituto Prevent Senior - IPS, São Paulo, Brazil|Clínica de la Costa, Barranquilla, Colombia|Clínica Shaio, Bogotá, Colombia|Fundación Cardioinfantil, Bogotá, Colombia|Fundacion Oftalmológica de Santander - Foscal, Bucaramanga, Colombia|Centro Médico Imbanaco, Cali, Colombia|CardioVid, Medellín, Colombia|Eternal Heart Care Centre and Research Ins Pvt Ltd., Jaipur, India|Jaipur National University, Jaipur, India|Sawai Mann Singh Hospital, Jaipur, India|Jaslok Hospital & Research Center, Mumbai, India|Saifee Hospital, Mumbai, India|Sengupta Hospital & Research Institute, Nagpur, India|D Y Patil University School of Medicine & D Y Patil Hospital, Navi Mumbai, India|Hospital Cardiológica Aguascalientes, Aguascalientes, Mexico|Centro Médico Nacional 20 de Noviembre, Mexico City, Mexico|Christus Muguerza Hospital Alta Especialidad, Monterrey, Mexico|Centro de Estudios Clinicos de Querétaro S.C., Santiago de Querétaro, Mexico|Centro Medico Hospital del Prado, Tijuana, Mexico
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 3600
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to first event|Number of in-hospital rate of BARC 3 or 5|Number of participants with Myocardial infarction|Number of participants with Deep Vein Thrombosis|Number of participants requiring Ventilation|Number of All Death|Cause of Death|Number of participants with Stroke|Number of participants with Pulmonary Emboli|Number of participants with Systemic Thromboembolism
NCT04788355 Prevention of Complications (SARS-CoV-2): Clinical Study Completed Phase 3 Jul/01/2020 Dec/23/2020
  • Alternative id - HA and A COVID 19
  • Interventions - Drug: Control group (standard hospital treatment)|Drug: Group Hydroxychloroquine|Drug: Group Hydroxychloroquine and apixaban|Drug: Group Apixaban
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Univás, Pouso Alegre, Minas Gerais, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 176
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Patients in home isolation will be followed for (telemedicine) 14 days. The Beck scale will assess anxiety. Questions will be asked to patients about their health conditions. The answers will be tabulated in a spreadsheet composed of the following result|Assessment of the presence or absence of secondary complications for patients in home isolation or hospitalized, after using the drugs.
NCT05088928 Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care Not yet recruiting Phase 2 Mar/01/2022 Aug/30/2022
  • Alternative id - RMUSCOTMANNECRUTRIAL|U1111-1272-7249
  • Interventions - Drug: Apixaban|Drug: Rivaroxaban
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Rawalpindi Medical University, Rawalpindi, Punjab, Pakistan
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 40
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Bleeding|Clotting
NCT04736901 Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19 Recruiting Dec/01/2020 Jun/01/2021
  • Alternative id - COVID-Anticoagulants
  • Interventions - Drug: Enoxaparin|Drug: Rivaroxaban|Drug: Apixaban
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Teachers Hospital, Cairo, Please Select, Egypt
  • Study designs - Observational Model: Cohort|Time Perspective: Other
  • Enrollment - 90
  • Age - 18 Years to 65 Years   (Adult, Older Adult)
  • Outcome measures - Change in clotting factors level|Change in gas exchange over time|Time to increase in oxygenation|Duration of hospitalization|Monitoring of adverse events|In hospital mortality rate|Monitoring of hemoglobin levels.|Monitoring of platelets levels
Export (.csv)